Heart Failure
General heart failure research and clinical updates
Also called HF, CHF, congestive heart failure, cardiac failure
Sources: 4 guideline recommendations · 12 landmark trials · 12 new papers · 5 key papers · updated Oct 20, 2026
Updated Nov 13, 2026: 3 experts on CADENCE
What 3 experts said about this trial's result
Expert labels are toward CADENCE's result, from named public quotes (n=3). As of Nov 13, 2026.
The strongest guideline recommendations for heart failure (Class I and IIa). Dosing is left to the guideline.
In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.
In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.
In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.
In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.
Unverified · drafted by AI from the sources cited below
Heart failure is a heterogeneous condition characterized by abnormalities in the heart's structure or function, resulting in the inability to pump sufficient blood to deliver oxygen to tissues in a timely manner and meet metabolic needs1.2 Chronic heart failure is more common than acute heart failure.1
Hypertension is a major risk factor for heart failure.1 Risk stratification is critical, and models integrating brain natriuretic peptide have been utilized to predict mortality in geriatric populations.
Earlier trials experts reacted to
2 experts with a clear stance so far. We show the split once 3 have one.
2 experts with a clear stance so far. We show the split once 3 have one.
Expert labels are toward each trial's result, from named public quotes.
Society guidelines, scientific statements and expert consensus on Heart failure from the last three months.
These guidelines refine the heart failure classification by LVEF and introduce a stage‑based framework to strengthen prevention, early detection, and timely intervention. They propose a revised nomenclature for therapies.
FDA approvals, label changes, device decisions and recalls on Heart failure from the last three months.
Manufacturer: Micro Labs Limited. Submission type: SUPPL. Route: ORAL. Form: TABLET, EXTENDED RELEASE
Manufacturer: AUROBINDO PHARMA LTD. Submission type: ORIG. Route: ORAL. Form: CAPSULE
How ACC/AHA/HFSA 2022 grades each treatment for heart failure. Open a row for the exact wording and who it applies to.
ARNI
sacubitril/valsartan
ACC/AHA/HFSA 2022 · Class I · LOE A
In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.
Beta blockers
bisoprolol, carvedilol, metoprolol succinate
Primary results of 12 trials behind the evidence on heart failure, as each trial’s own publication reports them.
Left of the line at 1 favours the intervention; square size tracks trial size.Favours the interventionNo significant differenceFavours the comparator
SUMMITprimary end point 1: CV death or worsening HF
tirzepatide vs placebo · 731 patients · N Engl J Med 2025
In patients with heart failure with preserved ejection fraction and obesity
Primary outcome: a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis)
Class of recommendation is how strongly the society advises the action (I is strongest, III is not recommended). Level of evidence is the kind of studies behind it (A is randomized trials, C is expert opinion or limited data).
4 recommendations on heart failure from 1 guideline, by strength.
Class IClass IIaClass IIbClass III
The strongest 4 recommendations
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
The Lancet — Kosiborod M
330 citations · 2024 · among the most cited on Heart failure
Heart failure with preserved ejection fraction: everything the clinician needs to know
The Lancet — Campbell P
285 citations · 2024 · among the most cited on Heart failure
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
Journal of the American College of Cardiology — Escobar-López L
198 citations · 2021 · among the most cited on Heart failure
Managing Patients With Short-Term Mechanical Circulatory Support
Journal of the American College of Cardiology — Balthazar T
118 citations · 2021 · among the most cited on Heart failure
Prevalence and clinical outcome associations of depression and anxiety in heart failure and atrial fibrillation: A meta-analysis
World Journal of Psychiatry — Chen C — Nov 2026
Influence of Systolic Blood Pressure and Pulse Pressure on Heart Failure Risk in Elderly Treated Hypertensive Patients
High Blood Pressure & Cardiovascular Prevention — Coccina F — Nov 2026
Sessions from public communities on Synapse. RSVP to join the live discussion.
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Guideline-directed therapies for patients with reduced ejection fraction include angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter inhibitors to reduce morbidity and mortality1.2 The use of 1 of the 3 beta blockers proven to reduce mortality is recommended.3 Additionally, a mineralocorticoid receptor antagonist is recommended if the estimated glomerular filtration rate is greater than 30 and serum potassium is less than 5.0.4 Short-term mechanical circulatory support is increasingly utilized for cardiogenic shock.5
ACC/AHA/HFSA 2022 · Class I · LOE A
In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.
Mineralocorticoid receptor antagonists
spironolactone, eplerenone
ACC/AHA/HFSA 2022 · Class I · LOE A
In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.
SGLT2 inhibitors
dapagliflozin, empagliflozin
ACC/AHA/HFSA 2022 · Class I · LOE A
In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.
HR 0.62 (0.41–0.95)
finerenone vs placebo · 6,001 patients · N Engl J Med 2024
In patients with heart failure and a left ventricular ejection fraction of 40% or greater
Primary outcome: a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes
Rate ratio 0.84 (0.74–0.95)
dapagliflozin vs placebo · 6,263 patients · N Engl J Med 2022
In patients with heart failure and a left ventricular ejection fraction of more than 40%
Primary outcome: a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death
HR 0.82 (0.73–0.92)
empagliflozin vs placebo · 5,988 patients · N Engl J Med 2021
In patients with heart failure and a preserved ejection fraction
Primary outcome: a composite of cardiovascular death or hospitalization for heart failure
HR 0.79 (0.69–0.90)
omecamtiv mecarbil vs placebo · 8,256 patients · N Engl J Med 2021
In patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less
Primary outcome: a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes
HR 0.92 (0.86–0.99)
empagliflozin vs placebo · 3,730 patients · N Engl J Med 2020
In patients with class II, III, or IV heart failure and an ejection fraction of 40% or less
Primary outcome: a composite of cardiovascular death or hospitalization for worsening heart failure
HR 0.75 (0.65–0.86)
vericiguat vs placebo · 5,050 patients · N Engl J Med 2020
In patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45%
Primary outcome: a composite of death from cardiovascular causes or first hospitalization for heart failure
HR 0.90 (0.82–0.98)
dapagliflozin vs placebo · 4,744 patients · N Engl J Med 2019
In patients with heart failure and a reduced ejection fraction
Primary outcome: a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death
HR 0.74 (0.65–0.85)
DECLARE-TIMI 58primary efficacy 2: CV death or HF hospitalization
dapagliflozin vs placebo · 17,160 patients · N Engl J Med 2019
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease
Primary outcome: MACE and a composite of cardiovascular death or hospitalization for heart failure
HR 0.83 (0.73–0.95)
catheter ablation vs medical therapy · 363 patients · N Engl J Med 2018
In patients with symptomatic paroxysmal or persistent atrial fibrillation
Primary outcome: a composite of death from any cause or hospitalization for worsening heart failure
HR 0.62 (0.43–0.87)
sacubitril–valsartan (LCZ696) vs enalapril · 8,442 patients · N Engl J Med 2014
In patients who had heart failure with a reduced ejection fraction
Primary outcome: a composite of death from cardiovascular causes or hospitalization for heart failure
HR 0.80 (0.73–0.87)
SUMMITprimary end point 2: KCCQ-CSS change at 52 weeks
tirzepatide vs placebo · 731 patients · N Engl J Med 2025
Primary outcome: the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS
“between-group difference, 6.9; 95% CI, 3.3 to 10.6; P<0.001”
STEP-HFpEFdual primary end point 1: KCCQ-CSS change
semaglutide vs placebo · 529 patients · N Engl J Med 2023
Primary outcome: the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS
“estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001”
STEP-HFpEFdual primary end point 2: % body-weight change
semaglutide vs placebo · 529 patients · N Engl J Med 2023
Primary outcome: the change in body weight
“estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001”
Results are quoted from each trial’s primary publication abstract (PubMed); the trial name links to the paper. Ratios below 1 favour the intervention.
In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.
In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.
In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.
In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.
Pathophysiology of the Lymphatic System in Patients With Heart Failure
Journal of the American College of Cardiology — Itkin M
107 citations · 2021 · among the most cited on Heart failure
Internal and Emergency Medicine — Melchio R — Nov 2026